| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 26 | 2009 | 1172 | 1.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 26 | 2019 | 2643 | 0.970 |
Why?
|
| Lung Neoplasms | 28 | 2009 | 2463 | 0.880 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 346 | 0.600 |
Why?
|
| Paclitaxel | 14 | 2008 | 497 | 0.460 |
Why?
|
| Taxoids | 7 | 2010 | 131 | 0.370 |
Why?
|
| Sulfonamides | 2 | 2008 | 337 | 0.300 |
Why?
|
| Antineoplastic Agents, Phytogenic | 6 | 2008 | 276 | 0.290 |
Why?
|
| Leukemia, Lymphoid | 11 | 1987 | 71 | 0.270 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2010 | 1104 | 0.270 |
Why?
|
| Antineoplastic Agents | 15 | 2008 | 2418 | 0.250 |
Why?
|
| Survival Rate | 12 | 2019 | 1985 | 0.250 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 310 | 0.250 |
Why?
|
| Combined Modality Therapy | 13 | 2010 | 1773 | 0.240 |
Why?
|
| Interprofessional Relations | 1 | 2007 | 128 | 0.240 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 137 | 0.240 |
Why?
|
| Carboplatin | 8 | 2008 | 331 | 0.220 |
Why?
|
| Quinazolines | 4 | 2008 | 216 | 0.220 |
Why?
|
| Clinical Trials as Topic | 5 | 2007 | 1179 | 0.220 |
Why?
|
| Neoplasms | 9 | 2007 | 3248 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2019 | 244 | 0.200 |
Why?
|
| Aged | 33 | 2019 | 20968 | 0.200 |
Why?
|
| Adenocarcinoma | 3 | 2010 | 1215 | 0.190 |
Why?
|
| Bone Marrow | 8 | 1998 | 458 | 0.180 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 7229 | 0.180 |
Why?
|
| Neoplasm Staging | 11 | 2010 | 2086 | 0.180 |
Why?
|
| Biomedical Research | 1 | 2007 | 441 | 0.180 |
Why?
|
| Leukemia | 6 | 1982 | 328 | 0.180 |
Why?
|
| Drug Administration Schedule | 10 | 2009 | 873 | 0.170 |
Why?
|
| Adult | 35 | 2010 | 28722 | 0.170 |
Why?
|
| Fluorouracil | 4 | 2019 | 555 | 0.170 |
Why?
|
| Capecitabine | 2 | 2019 | 99 | 0.170 |
Why?
|
| Organoplatinum Compounds | 4 | 2005 | 100 | 0.160 |
Why?
|
| Middle Aged | 33 | 2010 | 28369 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2008 | 1973 | 0.160 |
Why?
|
| Camptothecin | 3 | 2008 | 204 | 0.160 |
Why?
|
| Male | 46 | 2016 | 45865 | 0.150 |
Why?
|
| Humans | 75 | 2019 | 96109 | 0.150 |
Why?
|
| Disease-Free Survival | 7 | 2019 | 1196 | 0.150 |
Why?
|
| Female | 47 | 2019 | 50031 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 3 | 2002 | 137 | 0.140 |
Why?
|
| Etoposide | 3 | 2008 | 212 | 0.140 |
Why?
|
| Neutrophils | 3 | 2016 | 332 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 1993 | 423 | 0.130 |
Why?
|
| Vascular Remodeling | 1 | 2016 | 22 | 0.120 |
Why?
|
| Mast Cells | 1 | 2016 | 97 | 0.120 |
Why?
|
| Neovascularization, Physiologic | 1 | 2016 | 142 | 0.120 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2016 | 89 | 0.120 |
Why?
|
| Survival Analysis | 6 | 2009 | 1546 | 0.120 |
Why?
|
| Methotrexate | 9 | 2019 | 249 | 0.110 |
Why?
|
| Cyclophosphamide | 8 | 2019 | 313 | 0.110 |
Why?
|
| Leucovorin | 2 | 2005 | 227 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 3157 | 0.110 |
Why?
|
| Medical Oncology | 1 | 1998 | 408 | 0.110 |
Why?
|
| Doxorubicin | 7 | 2019 | 304 | 0.110 |
Why?
|
| Disease Progression | 6 | 2009 | 1561 | 0.100 |
Why?
|
| Maximum Tolerated Dose | 4 | 2008 | 271 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2008 | 611 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 477 | 0.100 |
Why?
|
| Treatment Outcome | 11 | 2019 | 9175 | 0.100 |
Why?
|
| Mitosis | 9 | 1978 | 159 | 0.090 |
Why?
|
| Agranulocytosis | 3 | 1984 | 20 | 0.090 |
Why?
|
| Infusions, Intravenous | 4 | 2005 | 423 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2009 | 216 | 0.090 |
Why?
|
| Hydroxyurea | 2 | 2008 | 239 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 1088 | 0.080 |
Why?
|
| Brain Neoplasms | 4 | 2006 | 854 | 0.080 |
Why?
|
| Neoplasm Metastasis | 6 | 2009 | 1094 | 0.080 |
Why?
|
| Child | 20 | 1998 | 7626 | 0.080 |
Why?
|
| Lymphoma | 3 | 1982 | 271 | 0.080 |
Why?
|
| Ifosfamide | 4 | 2003 | 48 | 0.080 |
Why?
|
| Prognosis | 11 | 2008 | 4029 | 0.070 |
Why?
|
| Cisplatin | 5 | 2010 | 611 | 0.070 |
Why?
|
| Cell Division | 4 | 1976 | 705 | 0.070 |
Why?
|
| Child, Preschool | 14 | 1998 | 3974 | 0.070 |
Why?
|
| Eicosanoids | 1 | 2008 | 17 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2009 | 1471 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 35 | 0.070 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 2008 | 36 | 0.070 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 100 | 0.070 |
Why?
|
| Aging | 1 | 1993 | 766 | 0.070 |
Why?
|
| Vinblastine | 3 | 2002 | 100 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 81 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2008 | 161 | 0.060 |
Why?
|
| Bone Marrow Cells | 7 | 1976 | 279 | 0.060 |
Why?
|
| Glutamates | 1 | 2007 | 90 | 0.060 |
Why?
|
| Infant | 13 | 1998 | 3363 | 0.060 |
Why?
|
| Cytarabine | 6 | 1982 | 225 | 0.060 |
Why?
|
| Guanine | 1 | 2007 | 207 | 0.060 |
Why?
|
| Asparaginase | 4 | 1982 | 35 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 101 | 0.060 |
Why?
|
| United States | 3 | 2008 | 7768 | 0.060 |
Why?
|
| Tegafur | 1 | 2005 | 17 | 0.060 |
Why?
|
| Drug Therapy, Combination | 8 | 1982 | 813 | 0.060 |
Why?
|
| Neuroblastoma | 3 | 1977 | 400 | 0.060 |
Why?
|
| Uracil | 1 | 2005 | 56 | 0.060 |
Why?
|
| Carbazoles | 1 | 2004 | 31 | 0.050 |
Why?
|
| Dipeptides | 1 | 2004 | 40 | 0.050 |
Why?
|
| Prodrugs | 1 | 2004 | 54 | 0.050 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2004 | 159 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 518 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2003 | 220 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 1976 | 842 | 0.050 |
Why?
|
| Age Factors | 3 | 2019 | 1963 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2008 | 1670 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 1981 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2002 | 67 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2002 | 56 | 0.050 |
Why?
|
| Anaphylaxis | 1 | 1982 | 33 | 0.050 |
Why?
|
| Insurance, Liability | 1 | 1981 | 10 | 0.040 |
Why?
|
| Radiotherapy Dosage | 3 | 2001 | 482 | 0.040 |
Why?
|
| ErbB Receptors | 3 | 2009 | 513 | 0.040 |
Why?
|
| Bone Marrow Examination | 5 | 1987 | 46 | 0.040 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 1981 | 58 | 0.040 |
Why?
|
| Research | 1 | 1981 | 265 | 0.040 |
Why?
|
| Cell Cycle | 2 | 1982 | 516 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 2860 | 0.040 |
Why?
|
| Tritium | 6 | 1982 | 134 | 0.040 |
Why?
|
| Thymidine | 6 | 1982 | 59 | 0.040 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.040 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1999 | 13 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 25 | 0.040 |
Why?
|
| Drug Combinations | 4 | 2005 | 214 | 0.040 |
Why?
|
| Administration, Oral | 3 | 2001 | 688 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 1993 | 228 | 0.040 |
Why?
|
| Antiphospholipid Syndrome | 1 | 1999 | 18 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1999 | 28 | 0.040 |
Why?
|
| American Cancer Society | 1 | 1998 | 13 | 0.040 |
Why?
|
| Vincristine | 6 | 1982 | 113 | 0.040 |
Why?
|
| Karyotyping | 2 | 1993 | 257 | 0.040 |
Why?
|
| Kinetics | 5 | 1982 | 1562 | 0.030 |
Why?
|
| Esophagitis | 1 | 1998 | 43 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1999 | 233 | 0.030 |
Why?
|
| Blood Platelets | 2 | 2016 | 156 | 0.030 |
Why?
|
| Autoantibodies | 1 | 1999 | 281 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1977 | 33 | 0.030 |
Why?
|
| Adolescent | 11 | 1998 | 9896 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2008 | 366 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2016 | 7 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 1996 | 14 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2016 | 22 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2016 | 30 | 0.030 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 257 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2016 | 51 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 80 | 0.030 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Professional-Family Relations | 1 | 1996 | 58 | 0.030 |
Why?
|
| Hindlimb | 1 | 2016 | 97 | 0.030 |
Why?
|
| Remission Induction | 2 | 2008 | 769 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1996 | 162 | 0.030 |
Why?
|
| Health Resources | 1 | 1996 | 82 | 0.030 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 1996 | 66 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 190 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2016 | 261 | 0.030 |
Why?
|
| Arteries | 1 | 2016 | 181 | 0.030 |
Why?
|
| Critical Care | 1 | 1999 | 447 | 0.030 |
Why?
|
| Monocytes | 1 | 2016 | 231 | 0.030 |
Why?
|
| Aneuploidy | 2 | 2007 | 64 | 0.030 |
Why?
|
| Bone Neoplasms | 3 | 1987 | 319 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2001 | 169 | 0.030 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 1316 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2007 | 340 | 0.030 |
Why?
|
| Time Factors | 5 | 2010 | 5580 | 0.030 |
Why?
|
| Logistic Models | 2 | 2008 | 1268 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1996 | 307 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 517 | 0.030 |
Why?
|
| Premedication | 2 | 2003 | 58 | 0.020 |
Why?
|
| Leukopenia | 1 | 1993 | 68 | 0.020 |
Why?
|
| Autoradiography | 3 | 1982 | 69 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 1993 | 226 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 1996 | 491 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2008 | 1346 | 0.020 |
Why?
|
| Acute Disease | 3 | 1982 | 872 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1996 | 635 | 0.020 |
Why?
|
| Blood Transfusion | 3 | 1984 | 182 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1971 | 272 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1753 | 0.020 |
Why?
|
| Risk | 3 | 1981 | 668 | 0.020 |
Why?
|
| Chloramphenicol | 1 | 1969 | 18 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 1970 | 183 | 0.020 |
Why?
|
| Prednisone | 3 | 1982 | 258 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 1969 | 35 | 0.020 |
Why?
|
| Diseases in Twins | 1 | 1969 | 65 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2007 | 3110 | 0.020 |
Why?
|
| Cetuximab | 1 | 2009 | 119 | 0.020 |
Why?
|
| Histocytochemistry | 2 | 1987 | 132 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2008 | 90 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2008 | 143 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 33 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1967 | 6 | 0.020 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 1967 | 2 | 0.020 |
Why?
|
| Microscopy, Electron | 2 | 1987 | 510 | 0.020 |
Why?
|
| DNA | 4 | 1982 | 1333 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2010 | 327 | 0.020 |
Why?
|
| Rhabdomyosarcoma | 2 | 1978 | 44 | 0.020 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1987 | 113 | 0.020 |
Why?
|
| Recurrence | 3 | 1999 | 1219 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 417 | 0.020 |
Why?
|
| Splenectomy | 2 | 1982 | 82 | 0.020 |
Why?
|
| Pemetrexed | 1 | 2007 | 76 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 883 | 0.020 |
Why?
|
| Blood Cell Count | 2 | 2001 | 79 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 223 | 0.020 |
Why?
|
| Hydrocortisone | 3 | 1973 | 300 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1967 | 191 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1987 | 294 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2005 | 50 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2007 | 547 | 0.010 |
Why?
|
| Nervous System Neoplasms | 1 | 1985 | 11 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 1010 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 740 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 930 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 46 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 901 | 0.010 |
Why?
|
| Drug Hypersensitivity | 1 | 2004 | 40 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2005 | 238 | 0.010 |
Why?
|
| Isoflurophate | 1 | 1964 | 3 | 0.010 |
Why?
|
| Phosphorus Isotopes | 1 | 1964 | 24 | 0.010 |
Why?
|
| Remission, Spontaneous | 3 | 1979 | 54 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1984 | 2 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 76 | 0.010 |
Why?
|
| Environment, Controlled | 1 | 1984 | 9 | 0.010 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1984 | 18 | 0.010 |
Why?
|
| Patient Isolation | 1 | 1984 | 14 | 0.010 |
Why?
|
| Granulocytes | 1 | 1984 | 41 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1984 | 15 | 0.010 |
Why?
|
| Genetics, Medical | 1 | 1964 | 51 | 0.010 |
Why?
|
| Quality of Life | 2 | 2005 | 1816 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 403 | 0.010 |
Why?
|
| Probability | 2 | 1982 | 365 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 1827 | 0.010 |
Why?
|
| Isoantibodies | 2 | 1999 | 127 | 0.010 |
Why?
|
| Neutropenia | 1 | 1964 | 218 | 0.010 |
Why?
|
| Biopsy | 1 | 1987 | 1220 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 27 | 0.010 |
Why?
|
| Macrolides | 1 | 2003 | 31 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2009 | 1021 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1429 | 0.010 |
Why?
|
| Erwinia | 1 | 1982 | 2 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2002 | 15 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1984 | 185 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 12537 | 0.010 |
Why?
|
| Exchange Transfusion, Whole Blood | 2 | 1972 | 18 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 2001 | 136 | 0.010 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 1981 | 5 | 0.010 |
Why?
|
| Liposomes | 1 | 2001 | 99 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 281 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 1982 | 231 | 0.010 |
Why?
|
| Safety | 1 | 2001 | 147 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 35 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 23 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1982 | 728 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 369 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1982 | 489 | 0.010 |
Why?
|
| Morals | 1 | 1981 | 102 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 299 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| North America | 1 | 2000 | 199 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1982 | 695 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 2001 | 376 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 713 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 63 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2001 | 819 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 89 | 0.010 |
Why?
|
| beta 2-Glycoprotein I | 1 | 1999 | 6 | 0.010 |
Why?
|
| Gangrene | 1 | 1999 | 6 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2008 | 4671 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1982 | 627 | 0.010 |
Why?
|
| Scleroderma, Localized | 1 | 1999 | 9 | 0.010 |
Why?
|
| Europe | 1 | 2000 | 349 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1981 | 312 | 0.010 |
Why?
|
| Hematoma, Subdural | 1 | 1999 | 28 | 0.010 |
Why?
|
| Filgrastim | 1 | 1998 | 59 | 0.010 |
Why?
|
| Fingers | 1 | 1999 | 70 | 0.010 |
Why?
|
| Leg | 1 | 1999 | 143 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 644 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 304 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1984 | 847 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1998 | 138 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 356 | 0.010 |
Why?
|
| Wilms Tumor | 1 | 1977 | 37 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 80 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 1977 | 92 | 0.010 |
Why?
|
| Ischemia | 1 | 1999 | 256 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 28891 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1997 | 236 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 1977 | 160 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1998 | 1034 | 0.010 |
Why?
|
| Thrombosis | 1 | 1999 | 326 | 0.010 |
Why?
|
| Phenotype | 1 | 1982 | 2578 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1999 | 463 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1977 | 297 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1998 | 2614 | 0.010 |
Why?
|
| Body Surface Area | 1 | 1995 | 37 | 0.010 |
Why?
|
| Phagocyte Bactericidal Dysfunction | 1 | 1974 | 2 | 0.010 |
Why?
|
| Phagocytosis | 2 | 1974 | 116 | 0.010 |
Why?
|
| Drug Antagonism | 1 | 1973 | 9 | 0.010 |
Why?
|
| Pediatrics | 1 | 1998 | 399 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 995 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 631 | 0.010 |
Why?
|
| Bone Marrow Diseases | 2 | 1985 | 40 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1973 | 170 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 1972 | 68 | 0.010 |
Why?
|
| Deoxyuridine | 1 | 1971 | 3 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1971 | 27 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1971 | 89 | 0.010 |
Why?
|
| Injections, Spinal | 2 | 1982 | 50 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3639 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1998 | 3927 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1971 | 271 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1970 | 300 | 0.000 |
Why?
|
| gamma-Globulins | 1 | 1967 | 16 | 0.000 |
Why?
|
| Blood Group Antigens | 1 | 1967 | 16 | 0.000 |
Why?
|
| Medulloblastoma | 1 | 1967 | 44 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1972 | 2939 | 0.000 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1967 | 81 | 0.000 |
Why?
|
| Pedigree | 1 | 1967 | 982 | 0.000 |
Why?
|
| Pharmacogenetics | 1 | 1969 | 456 | 0.000 |
Why?
|
| Inflammation | 1 | 1970 | 1063 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1970 | 1667 | 0.000 |
Why?
|
| Mercaptopurine | 1 | 1982 | 53 | 0.000 |
Why?
|
| Meningeal Neoplasms | 1 | 1979 | 73 | 0.000 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1978 | 13 | 0.000 |
Why?
|
| Orbital Neoplasms | 1 | 1978 | 16 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1979 | 154 | 0.000 |
Why?
|
| Facial Neoplasms | 1 | 1978 | 26 | 0.000 |
Why?
|
| Ear Neoplasms | 1 | 1978 | 14 | 0.000 |
Why?
|
| Ear, Middle | 1 | 1978 | 26 | 0.000 |
Why?
|
| Testicular Neoplasms | 1 | 1979 | 123 | 0.000 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1978 | 47 | 0.000 |
Why?
|
| Infusions, Parenteral | 1 | 1976 | 51 | 0.000 |
Why?
|
| Daunorubicin | 1 | 1976 | 78 | 0.000 |
Why?
|
| Sex Factors | 1 | 1979 | 1133 | 0.000 |
Why?
|
| Blood Bactericidal Activity | 1 | 1974 | 5 | 0.000 |
Why?
|
| Staphylococcus | 1 | 1974 | 24 | 0.000 |
Why?
|
| Candida albicans | 1 | 1974 | 32 | 0.000 |
Why?
|
| Alkaline Phosphatase | 1 | 1974 | 136 | 0.000 |
Why?
|
| Chemotaxis | 1 | 1974 | 74 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1974 | 99 | 0.000 |
Why?
|
| Staining and Labeling | 1 | 1974 | 172 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1974 | 288 | 0.000 |
Why?
|
| Lysosomes | 1 | 1974 | 124 | 0.000 |
Why?
|
| Leukocytes | 1 | 1974 | 218 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1974 | 1010 | 0.000 |
Why?
|
| Cell Nucleus | 1 | 1974 | 623 | 0.000 |
Why?
|